1. A study of the drug tildrakizumab in psoriasis patients. (1st March 2020) Authors: Reich, K.; Warren, R.B.; Iversen, L.; Puig, L.; Pau‐Charles, I.; Igarashi, A.; Ohtsuki, M.; Falqués, M.; Harmut, M.; Rozzo, S.; Lebwohl, M.G.; Cantrell, W.; Blauvelt, A.; Thaçi, D. Journal: British journal of dermatology Issue: Volume 182:Number 3(2020) Page Start: e100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A study of the drug tildrakizumab in psoriasis patients. (28th February 2020) Authors: Reich, K.; Warren, R.B.; Iversen, L.; Puig, L.; Pau‐Charles, I.; Igarashi, A.; Ohtsuki, M.; Falqués, M.; Harmut, M.; Rozzo, S.; Lebwohl, M.G.; Cantrell, W.; Blauvelt, A.; Thaçi, D. Journal: British journal of dermatology Issue: Volume 182:Number 3(2020) Page Start: e100 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acquired hypopigmented suprapubic macules. (1st July 2014) Authors: Pau‐Charles, I.; Vicente, A.; Jou, C.; González‐Enseñat, M. A. Journal: Clinical and experimental dermatology Issue: Volume 39:Number 5(2014) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Acquired hypopigmented suprapubic macules. (23rd April 2014) Authors: Pau‐Charles, I.; Vicente, A.; Jou, C.; González‐Enseñat, M. A. Journal: Clinical and experimental dermatology Issue: Volume 39:Number 5(2014) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Anti‐MDA5 positive clinically amyopathic dermatomyositis presenting with severe cardiomyopathy. (29th October 2013) Authors: Pau‐Charles, I.; Moreno, P.J.; Ortiz‐Ibáñez, K.; Lucero, M.C.; Garcia‐Herrera, A.; Espinosa, G.; Nicolás, J.M.; Castro, P.; Grau, J.M.; Casciola‐Rosen, L.; Mascaró, J.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 28:Number 8(2014:Aug.) Page Start: 1097 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE). (15th November 2016) Authors: Mrowietz, U.; Szepietowski, J.C.; Loewe, R.; van de Kerkhof, P.; Lamarca, R.; Ocker, W.G.; Tebbs, V.M.; Pau‐Charles, I. Journal: British journal of dermatology Issue: Volume 176:Number 3(2017) Page Start: 615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate‐to‐severe chronic plaque psoriasis: a randomized, double‐blind, Fumaderm®‐ and placebo‐controlled trial (BRIDGE). (1st March 2017) Authors: Mrowietz, U.; Szepietowski, J.C.; Loewe, R.; van de Kerkhof, P.; Lamarca, R.; Ocker, W.G.; Tebbs, V.M.; Pau‐Charles, I. Journal: British journal of dermatology Issue: Volume 176:Number 3(2017) Page Start: 615 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. First‐line treatment in lymphomatoid papulosis: a retrospective multicentre study. (10th October 2017) Authors: Fernández‐de‐Misa, R.; Hernández‐Machín, B.; Servitje, O.; Valentí‐Medina, F.; Maroñas‐Jiménez, L.; Ortiz‐Romero, P. L.; Sánchez Schmidt, J.; Pujol, R. M.; Gallardo, F.; Pau‐Charles, I.; García Muret, M. P.; Pérez Gala, S.; Román, C.; Cañueto, J.; Blanch Rius, L.; Izu, R.; Ortiz‐Brugués, A.; Mart... Journal: Clinical and experimental dermatology Issue: Volume 43:Number 2(2018) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. First‐line treatment in lymphomatoid papulosis: a retrospective multicentre study. (1st March 2018) Authors: Fernández‐de‐Misa, R.; Hernández‐Machín, B.; Servitje, O.; Valentí‐Medina, F.; Maroñas‐Jiménez, L.; Ortiz‐Romero, P. L.; Sánchez Schmidt, J.; Pujol, R. M.; Gallardo, F.; Pau‐Charles, I.; García Muret, M. P.; Pérez Gala, S.; Román, C.; Cañueto, J.; Blanch Rius, L.; Izu, R.; Ortiz‐Brugués, A.; Mart... Journal: Clinical and experimental dermatology Issue: Volume 43:Number 2(2018) Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). (1st August 2021) Authors: Thaci, D.; Piaserico, S.; Warren, R.B.; Gupta, A.K.; Cantrell, W.; Draelos, Z.; Foley, P.; Igarashi, A.; Langley, R.G.; Asahina, A.; Young, M.; Falqués, M.; Pau‐Charles, I.; Mendelsohn, A.M.; Rozzo, S.J.; Reich, K. Journal: British journal of dermatology Issue: Volume 185:Number 2(2021) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗